STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

RAD-140

Also known as

Testolone · RAD140 · RAD 140 · Vosilasarm (INN / development naming) · EP0062 (reformulated clinical code) · Testalone (common misspelling in literature and forums) · Radius RAD140 (developer-adjacent search string)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral SARMs (adjacent discourse)

Systemic oral SARM — whole-body exposure with muscle/bone-biased AR agonism talk; not a local inject and not a peptide.

What people say RAD-140 (testolone/vosilasarm) is an investigational oral SARM. Human trial evidence is from metastatic breast cancer, not athletic performance, and gray-market identity is not assured. Doses people talk about
Eight-week solo report10 mg/day, later 20–25 mg/day

Amount increased in weeks 5–6 during a cut; subjective strength change, no bloodwork or assay.

Stacked bloodwork report10 mg/day oral RAD-140

Also 6.25 mg/day enclomiphene; ALT later reached 417 or higher and identity was questioned.

Phase I oncology cohorts50, 100 or 150 mg/day oral

Twenty-two heavily pretreated postmenopausal metastatic-breast-cancer patients; not an athletic study.

Reported recreational amounts are not approved. Products were not assayed, one report included enclomiphene, and oncology doses/population are not transferable.

Half-life & effect duration

Half-life in the body
  • Human studyAbout 44.7 hours
  • Secondary clinical summariesAbout 45–60 hours
  • Older vendor / forum estimateAbout 16–20 hours
Felt duration people report
  • Solo-use accountNo change for 2 weeks, strength changes in weeks 3–6, low drive after stopping
  • Stacked-use accountFelt well for 4 weeks despite later marked liver-enzyme elevation
Timing context & sources
How it may feel Accounts unfold over weeks: one solo user reported no change for two weeks then greater strength; a stacked user felt good for four weeks before marked liver-enzyme elevation. One post-stop report described low drive/slower recovery for about a week.
Cycles people discuss Six-to-eight-week courses dominate forum discussion, with longer runs bringing more suppression/safety concern. These are recreational patterns, not clinical cycles; PCT talk does not validate a regimen. Timing The reviewed clinical and community exposures used once-daily oral schedules. Split dosing remains a community preference, not a requirement established by the oncology PK study. Stacks Reports combine RAD-140 with MK-677, another SARM, cardarine, testosterone or recovery drugs. Combinations confound benefits and harms; enclomiphene/supplements did not verify identity or prevent the inspected liver event. Watch for Liver — recreational case reports: Multiple published DILI cases (cholestatic or mixed pattern) after unsupervised RAD-140 or RAD+LGD products (e.g. Barbara et al. 2020 Alpha Bolic/Alpha Elite; Flores et al.; Leung et al. 2022 peak bilirubin extreme; Australian Prescriber severe injury case). Jaundice, pruritus, and high bilirubin weeks into use are documented.
Related
LGD-4033OstarineYK-11MK-677

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The first-in-human oncology study reported a 44.7-hour RAD-140 half-life.

Twenty-two postmenopausal patients with heavily pretreated metastatic breast cancer received 50, 100 or 150 mg orally once daily; authors said 44.7 hours supported QD dosing.

Clinical formulation, oncology doses, disease state and population differ from unverified recreational products and users.

Felt duration people report

Community reports do not establish a reproducible onset or felt-duration window.

One solo account described no change for two weeks, strength changes in weeks 3–6 and low drive after stopping; a stacked account felt well for four weeks before marked liver-enzyme elevation.

Anonymous reports, changing dose, training/diet, co-use and unverified identity prevent causal timing; laboratory injury may lack a distinctive felt warning.

Other context in this card

What people say 11

  • Lean mass (community): Multi-week oral logs often claim several pounds of lean tissue with training/surplus; diet and prior training confounds are large. forum
  • Strength: Faster progressive overload on compounds (bench/squat/dead) in the first 2–4 weeks is one of the most repeated claims. forum
  • Dry / hard look: Later weeks — denser, more vascular appearance vs aromatizing AAS or “wetter” LGD is standard forum typology, not imaging-trial proof. forum
  • Recomp: Fat loss with muscle hold on a deficit is frequently logged; calories and cardio usually co-credited. forum
  • Vs ostarine (MK-2866): Cast as much stronger for size/strength; also more suppression and side talk. forum
  • Vs LGD-4033: LGD = fuller/waterier mass; RAD = denser/drier strength look — popular pairing contrast, not a head-to-head RCT. forum
  • Vs S-4 / YK-11 / S-23: Often ranked “strong but more usable” than YK/S-23 for first hard cycle; S-4 more cut/vision-side lore. forum
  • Animals (anabolic): Oral RAD140 increased levator ani muscle weight with wide separation from prostate stimulation in castrate and intact rat models (Miller et al., ACS Med Chem Lett 2011). animal
  • Animals (CNS): In cultured hippocampal neurons and kainate-lesioned rats, RAD140 matched testosterone’s neuroprotective signal on apoptotic/excitotoxic insults (Jayaraman et al., Endocrinology 2014) — research interest only, not a nootropic product claim. animal
  • Clinic (not gym): Phase 1 breast-cancer AR-pathway work showed AR engagement (SHBG↓, PSA↑ in many patients) and limited antitumor signals — medical oncology, not physique outcomes. trial
  • What is missing: No large placebo-controlled athletic lean-mass/strength trial at 5–30 mg/day recreational bands. trial

Doses people talk about 12

  • Inspected oral reports plus broader band: One eight-week solo reviewer began at 10 mg/day, then described 20 mg/day in week 5 and 25 mg/day later; another author reported 10 mg/day with enclomiphene. These unverified products do not define a safe dose, and broader forum charts remain ~5–10 mg/day. forum
  • Beginner oral band: ~5–10 mg once daily is the usual first-cycle discussion range; many first logs start at 10 mg. forum
  • Intermediate band: ~10–20 mg/day for stronger lean-mass/strength aims in multi-week runs. forum
  • Upper / advanced talk: ~20–30 mg/day in aggressive or second-cycle logs; side and suppression talk rises without proportional proof of better risk/benefit. forum
  • Above 30 mg/day (recreational): Uncommon in careful write-ups; occasionally bragged; no community consensus that higher is smarter. forum
  • Women (recreational talk): Sparse anecdotes at roughly ~5–10 mg/day with high virilization concern (voice, hair, clitoral changes); many forum voices steer women toward milder agents instead. forum
  • Schedule: Once daily is default because of long clinical half-life; splitting AM/PM is minority practice and not required by PK. forum
  • Capsule products: Fixed 5–10 mg capsules appear in stack logs; still unverified without third-party testing. forum
  • Label risk: Gray-market mg on bottle ≠ verified pure RAD-140; adulteration with other SARMs/prohormones/steroids is a documented industry problem. forum
  • Framing: Community-reported research-discussion ranges only — not advice, not prescriptions, not safety-validated protocols. forum
  • Clinical oncology (not gym): First-in-human Phase 1 (LoRusso et al., Clin Breast Cancer 2022) tested roughly 50–150 mg/day oral in postmenopausal mBC; MTD/RDE ~100 mg once daily. trial
  • EP0062 reformulation: Later vosilasarm (EP0062) dose-finding used lower absolute daily amounts (e.g. 10 mg BID selected as optimal Phase 2 dose in ASCO 2025 abstract of NCT05573126) — formulation/PK differ from classic RAD140 gym products. trial

How it may feel 8

  • First 1–2 weeks conflict: One eight-week solo reviewer reported no change for two weeks; a separate 10 mg/day plus enclomiphene author described good mood, strength and pumps across four weeks before marked liver-enzyme elevation. forum
  • Weeks 1–2: Strength and training “quality” comments often precede scale or mirror moves; pumps may feel denser. forum
  • Weeks 3–4: Recomp/lean-mass anecdotes and first acne or hair-shed notes; common first bloodwork checkpoint in careful logs. forum
  • Weeks 6–8: Peak strength/size claims on typical cycles; fatigue, libido drop, irritability, and lipid/liver anxiety also cluster here. forum
  • Weeks 8–12: Longer bulk-style runs — more suppression, lipid crash, and “need PCT” talk; diminishing returns debated. forum
  • On-cycle crash while still dosing: Some logs describe mid-cycle lethargy or flat libido when suppression outruns perceived anabolism. anecdote
  • Post-cycle report: One solo reviewer described a few days of better sleep, then about a week of difficulty getting out of bed, lower motivation and slower recovery. No bloodwork was provided, so suppression was not established. anecdote
  • Post-cycle months: Training-kept size varies widely; many attribute retention to diet/training more than the molecule. anecdote

Cycles people discuss 12

  • Typical length: 6–8 weeks is the most common physique discussion window. forum
  • Longer runs: 8–12 weeks for bulk-style aims; past ~12 weeks side/suppression talk dominates. forum
  • Shorter intros: 4–6 week “test runs” appear when users are risk-averse or first-timing a strong SARM. forum
  • Time off: Off-time ≥ on-time (plus recovery/PCT) is the usual forum rule of thumb — not a clinical standard. forum
  • PCT default talk: SERMs after cycle — tamoxifen (Nolvadex) and/or clomiphene (Clomid) language for several weeks is near-default in RAD threads. forum
  • PCT timing debate: With ~45–60 h clinical half-life, some wait ~5–14 days after last dose before SERMs; older 16–20 h guides said sooner — both patterns still circulate. forum
  • Solo vs stack: Solo first cycle is common advice; dual SARMs or RAD+MK-677 = harder to attribute gains and usually more suppression/side load. forum
  • Bloodwork culture: Pre, mid (~week 4–6), and post labs (total/free T, LH/FSH, lipids, AST/ALT, CBC) are repeatedly recommended in careful communities. forum
  • Re-runs: After subjective recovery and/or labs in logs; multi-year repeated gray-market safety is not established. forum
  • Bridge / cruise talk: Some advanced users discuss low-dose bridges or TRT-base + RAD — that is steroid-adjacent practice, not SARM-only “safe” lore. forum
  • PCT folklore: AAS-board style PCT talk after RAD is common; evidence quality is forum-grade. forum
  • Example PCT shapes (forum only): Nolvadex ~10–20 mg/day for ~4–6 weeks, or lower-dose Clomid, or short dual SERM runs; doses vary wildly and are not medical protocols. forum

Timing 9

  • Forum conflict (legacy): Pre-Phase-1 guides widely claimed ~16–20 hour half-life; still copy-pasted on vendor blogs despite human PK. forum
  • Practical dosing logic: Long clinical duration → once-daily oral is standard; split dosing is optional preference, not PK necessity. forum
  • Steady state: Multi-day half-life implies levels build over roughly the first week+ of daily dosing. forum
  • PCT / clearance talk: Longer half-life arguments push later SERM starts vs short-half-life AAS mental models. forum
  • HPTA lag: Suppression of LH/FSH/T can outlast the last dose; recovery timelines in logs span weeks to months. forum
  • Clinical half-life (primary): Phase 1 PK reported mean t½ ≈ 44.7 hours, supporting once-daily (QD) dosing (LoRusso et al., 2022). trial
  • Reference range often cited: ~45–60 hour elimination half-life for vosilasarm/RAD140 in secondary clinical summaries. trial
  • SHBG / PSA (clinic): Phase 1 oncology: SHBG fell in all measured patients (18/18); PSA rose in most (16/20) — target engagement markers, not gym benefits. trial
  • Anti-doping: SARM metabolite detection windows can be long relative to last dose; tested athletes treat RAD as high-risk regardless of “oral only” framing. trial

More on what it is 8

  • Why people care: Forums rank it among the strongest recreational oral SARMs for lean mass and strength vs ostarine, with a “drier” look narrative than LGD. forum
  • Research lens: Vendor “Testolone” bottles are unregulated research chemicals; label mg ≠ verified identity or purity. forum
  • Bro framing: Testolone — the “aggressive recomp SARM” people compare to a mild cycle, with suppression baggage. forum
  • What it is: Investigational oral nonsteroidal SARM (RAD-140 / Testolone / vosilasarm); oxadiazole-aniline scaffold from Radius Health–line development. trial
  • Mechanism talk: High-affinity AR agonist framed as tissue-selective (muscle/bone over prostate in animals); still suppresses the HPTA at common research-chem doses. animal
  • Evidence: Preclinical muscle/neuro papers + Phase 1 in postmenopausal ER+/HER2− breast-cancer patients; no large athletic RCTs for physique outcomes. trial
  • Clinical naming: Vosilasarm / EP0062 continues breast-cancer SARM programs at different formulations and doses than gray-market gym charts. trial
  • Not: Not testosterone, not a 17α-alkylated oral steroid ester, not a peptide, not FDA-approved for bodybuilding, fat loss, or hypogonadism. trial

Stacks 11

  • RAD + MK-677 (Ibutamoren): Classic “mass” stack — RAD anabolism + MK appetite/sleep/GH-axis narrative; water retention, fasting glucose, and hunger confounds are frequent. Community charts often pair ~10–20 mg RAD with ~10–25 mg MK daily. forum
  • RAD + LGD-4033: Dual strong-SARM bulk; high suppression, lipid, and side-load talk; hard to know which agent drove gains. forum
  • RAD + cardarine (GW-501516): Cutting/recomp + endurance/fat-oxidation narrative; GW is not a SARM and carries its own long-term safety debates. forum
  • RAD + ostarine (MK-2866): “Potency + milder bridge” idea; attribution of results is murky; stacked suppression still expected. forum
  • RAD + YK-11: Aggressive strength/myostatin-lore stack; side and suppression reputation is harsh in forums. forum
  • RAD + S-4 (andarine): Recomp/cut aesthetics talk; S-4 vision-side lore adds separate risk. forum
  • RAD as oral kickstart on TRT/blast: Some advanced AAS logs add RAD for dry strength — not a beginner SARM-only pattern. forum
  • Liver support talk: TUDCA, NAC, milk thistle appear constantly next to oral SARM cycles — evidence of protection specifically for RAD is anecdotal. forum
  • Lipid support talk: Fish oil, citrus bergamot, cardio, and diet changes discussed when HDL tanks on bloodwork. forum
  • PCT adjuncts: SERMs as above; some add enclomiphene, hCG, or OTC “test boosters” — quality of evidence varies from prescription-drug lore to pure marketing. forum
  • What stacks do not prove: Multi-compound logs cannot isolate RAD’s contribution; vendor “premade SARM stacks” often hide ratios and underdose. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • HPTA suppression: Meaningful LH/FSH/testosterone suppression is expected in community bloodwork at common 10–20 mg bands — low libido, fatigue, soft post-cycle gains, and “dead bedroom” complaints are frequent. forum
  • “Non-methylated = safe liver” myth: Marketing claim that lack of 17α-alkylation makes RAD liver-safe is contradicted by clinical enzyme rises and bodybuilding DILI reports. forum
  • Skin / hair: Acne and accelerated male-pattern shedding in susceptible users are standard side threads. forum
  • Mood / CNS: Irritability, aggression (“RAD rage” lore), anxiety, or insomnia in a subset; others report flat mood when suppressed. anecdote
  • Sexual function: On-cycle or post-cycle ED/libido crash tied to suppression; not fixed by “selectivity” marketing. forum
  • Vision: True classic S-4 yellow-tint lore is less central to RAD, but any vision change still prompts stop-and-evaluate talk in stacks. forum
  • Women-specific: Virilization risk (voice deepening, body/facial hair, menstrual disruption) even at low recreational mg — irreversible changes are a hard forum warning. forum
  • Cardiac / BP: Less systematic data than lipids; some users report resting HR or BP anxiety; long-term CV risk of recreational SARM use is unknown. forum
  • Not risk-free: Tissue-selective AR marketing ≠ absence of suppression, hepatotoxicity, lipid harm, or long-term unknowns. No approved recreational dose exists. forum
  • Bloodwork culture: People who take it seriously check lipids, HCT, and hormones — shutdown stories are the cautionary genre. forum
  • Unapproved-drug status: SARMs are not FDA-approved for human use and are not legal dietary-supplement ingredients. This card maps forum talk only — not a sourcing guide, not a safety claim, and not a promise of results. trial
  • Animal suppression signal: In young male cynomolgus monkeys, 28-day oral RAD140 suppressed testosterone into a low-normal band across tested doses while still supporting body weight (Miller et al.) — selective muscle action ≠ no systemic endocrine effect. animal
  • Liver — clinical oncology: Phase 1 mBC: elevated AST in ~59%, ALT ~46%, total bilirubin ~27% of patients; Grade 3 AST/ALT and hypophosphatemia among notable TEAEs (LoRusso et al., 2022). trial
  • Liver — recreational case reports: Multiple published DILI cases (cholestatic or mixed pattern) after unsupervised RAD-140 or RAD+LGD products (e.g. Barbara et al. 2020 Alpha Bolic/Alpha Elite; Flores et al.; Leung et al. 2022 peak bilirubin extreme; Australian Prescriber severe injury case). Jaundice, pruritus, and high bilirubin weeks into use are documented. trial
  • Lipids: Adverse HDL depression (and broader dyslipidemia talk) is common in bloodwork-sharing logs; monkey chemistry also showed large HDL drops at higher mg/kg. animal
  • Source / product risk: Mislabeling, multi-SARM blends sold as pure RAD, prohormone/steroid adulteration, and wrong mg strength are documented industry problems (including named commercial “Alpha” products in DILI literature). trial
  • Sport / law: WADA-prohibited anabolic agent class; not approved as a dietary supplement; research-chemical sales legality varies by jurisdiction; FDA has warned against SARMs in bodybuilding products. trial
  • Evidence honesty: Physique outcome claims are almost entirely uncontrolled logs; strongest human safety PK/AE data are oncology Phase 1 at doses and populations unlike gym use. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →